- Home
- ZNTL vs VNDA Comparison
ZNTL vs VNDA Comparison
Compare ZNTL & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- VNDA
- Stock Information
- Founded
- ZNTL 2014
- VNDA 2002
- Country
- ZNTL United States
- VNDA United States
- Employees
- ZNTL N/A
- VNDA N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- ZNTL Health Care
- VNDA Health Care
- Exchange
- ZNTL Nasdaq
- VNDA Nasdaq
- Market Cap
- ZNTL 238.2M
- VNDA 270.2M
- IPO Year
- ZNTL 2020
- VNDA 2006
- Fundamental
- Price
- ZNTL $3.12
- VNDA $4.73
- Analyst Decision
- ZNTL Buy
- VNDA Buy
- Analyst Count
- ZNTL 7
- VNDA 1
- Target Price
- ZNTL $10.86
- VNDA $13.00
- AVG Volume (30 Days)
- ZNTL 1.2M
- VNDA 641.3K
- Earning Date
- ZNTL 11-04-2024
- VNDA 11-06-2024
- Dividend Yield
- ZNTL N/A
- VNDA N/A
- EPS Growth
- ZNTL N/A
- VNDA N/A
- EPS
- ZNTL N/A
- VNDA N/A
- Revenue
- ZNTL $40,560,000.00
- VNDA $182,022,000.00
- Revenue This Year
- ZNTL N/A
- VNDA $6.70
- Revenue Next Year
- ZNTL N/A
- VNDA $51.03
- P/E Ratio
- ZNTL N/A
- VNDA N/A
- Revenue Growth
- ZNTL N/A
- VNDA N/A
- 52 Week Low
- ZNTL $2.83
- VNDA $3.30
- 52 Week High
- ZNTL $18.24
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- VNDA 48.57
- Support Level
- ZNTL $2.92
- VNDA $4.68
- Resistance Level
- ZNTL $3.23
- VNDA $4.98
- Average True Range (ATR)
- ZNTL 0.17
- VNDA 0.18
- MACD
- ZNTL 0.00
- VNDA 0.05
- Stochastic Oscillator
- ZNTL 38.33
- VNDA 40.00
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.